Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093418 · ClinicalTrials.gov registry record · Phase 2
S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 296
- Enrollment target
NCT00093418: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00093418 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 296 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00093418, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 296 participants
- Enrollment target
Study Summary
This randomized phase II trial is studying 4 different tipifarnib regimens to compare how well they work in treating older patients with acute myeloid leukemia. Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for their growth
Interventions
- DRUG tipifarnib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 296 participants |
| Start Date | 2004-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00093418
The ClinicalTrials.gov registry entry for NCT00093418 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 296 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tipifarnib is the first listed.
NCT00093418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00093418 about?
NCT00093418 is a clinical study titled "S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia". This randomized phase II trial is studying 4 different tipifarnib regimens to compare how well they work in treating older patients with acute myeloid leukemia. Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for their growth
What is the current status of trial NCT00093418?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 296 participants. The study started on 2004-09.
What interventions are being tested in trial NCT00093418?
The interventions under investigation include: tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00093418?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.